Blackstone Life Sciences

Blackstone Life Sciences

Blackstone Life Sciences was established as a formal vehicle to consolidate the firm's growing healthcare investing activity, building on Clarus, the life sciences private equity platform Blackstone acquired in 2018. The group is led by Nicholas Galakatos, who co-founded Clarus and now serves as Global Head of Blackstone Life Sciences. Unlike early-stage venture funds that build from scientific discovery, BXLS targets products and companies that have already cleared significant regulatory or clinical milestones, providing growth capital to scale commercialization or late-stage trials. The strategy covers three distinct deployment lanes: royalty and structured credit transactions that monetize existing drug revenue streams, control equity investments in commercial-stage biopharma and medical device companies, and growth equity for private healthcare technology businesses. The portfolio reflects this breadth — known investments include royalty interests in Bristol Myers Squibb's cardiovascular drug Eliquis, an equity stake in Alnylam Pharmaceuticals secured through a royalty deal, and the acquisition of a majority stake in Bumble Bee Foods' parent for a healthcare turnaround play. The team invests primarily in North America and Western Europe, with additional deal activity in Japan. The platform sits within Blackstone's $200 billion private equity division, benefiting from shared sourcing, diligence, and the firm's institutional relationships. While headcount is not publicly broken out, the team operates across offices in Cambridge, London, and Minneapolis, drawing on Blackstone's broader operational support. In February 2025, the group partnered with the UK government on a £200 million Life Sciences Innovation Fund targeting UK-based biotech and medtech companies, underscoring an active public-private posture (per the firm, February 2025). What distinguishes Blackstone Life Sciences from dedicated healthcare funds is the structural permanence of its parent. The team does not face the fund-life constraints of a traditional GP — it can hold royalty streams for decades, match the long duration of drug commercialization, and supply follow-on capital without returning to market. This architecture, combined with Blackstone's balance sheet, lets it write equity checks ranging from $100 million to over $1 billion, a scale that few life sciences-focused investors can offer.